Clinical TrialID 8090
Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults
NCT05743985
Health, Subjective|Inflammatory Response|Adverse Effect|Side Effect
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 8090
- Evidence Id
- 8090
- Core Evidence Id
- 8090
- Source Clinical Trial Id
- 8089
- Herb2 Clinical Trial Id
- HBCT008089
- Nct Id
- NCT05743985
- Title
- Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults
- Status
- Completed
- Phase
- Study Result
- No
- Study Condition
- Health, Subjective|Inflammatory Response|Adverse Effect|Side Effect
- Study Type
- Interventional
- Study Design
- Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- OTHER: Cannabigerol
- Intervention Allocation
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 69
- Outcome Measure
- Change from Baseline Medical Symptom Questionnaire (MSQ) Score at 8 weeks, Change from baseline scores as measured by the Medical Symptom Questionnaire after 8 weeks. A total score of 20 or less is not clinically significant, 20 to 49 indicates mild toxicity, 50 to 99 indicates moderate toxicity, and 100 and above indicates severe toxicity., 8 weeks|Change from Baseline RAND 36-Item Short Form Survey (SF-36) Scores at 8 weeks, Change from baseline scores as measured by the RAND 36-Item Short Form Survey after 8 weeks. Scores range from 0-100 for the 8 scales included (physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health), with higher scores representing a more favorable health state., 8 weeks|Change from Baseline High-Sensitivity C-reactive Protein (hsCRP) at 8 weeks, Blood concentration, measured in mg/L, 8 weeks|Change from Baseline Erythrocyte Sedimentation Rate (ESR) at 8 weeks, Blood concentration, measured in mm/hour, 8 weeks|Change from Baseline Prostate-Specific Antigen (PSA) Score at 8 weeks [Male Subjects], Blood concentration, measured in ng/mL, 8 weeks
- Sponsor Collaborator
- Formula30A LLC
- Funded By
- INDUSTRY
- Location
- Institute for Hormonal Balance, Arlington, Texas, 76016, United States|NP Care Clinic, Denton, Texas, 76201, United States|Infectious Disease Specialists, Edinburg, Texas, 78539, United States|Modern Medicine, Forney, Texas, 75126, United States|Texas Gynecology, Frisco, Texas, 75034, United States|Melville Medicine, Southlake, Texas, 76092, United States|Java Med, Ceiba, 00735, Puerto Rico
- Other Id
- F30A-CBG-EAS2022
- Start Date
- 2022-08-01
- Primary Completion Date
- 2023-12-31
- Completion Date
- 2024-04-30
- First Posted
- 2023-02-24
- Results First Posted
- Last Update Posted
- 2024-06-13
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05743985
- Title Cn
- Title En
- Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults
- Bilingual Status
- semi_complete